Antibody-drug conjugate

Oxford BioTherapeutics to Present Initial Positive Data from Phase I Trial at ASCO 2022

Retrieved on: 
Friday, May 27, 2022

Company has advanced OBT076 into single agent expansion cohorts in both checkpoint- and chemotherapy-nave and resistant patients.

Key Points: 
  • Company has advanced OBT076 into single agent expansion cohorts in both checkpoint- and chemotherapy-nave and resistant patients.
  • Subsequent disease-specific Phase 2a trials are planned in non-small cell lung, ovarian and gastric cancer patients.
  • OBT has a strong oncology focused management team and board with significant experience in developing IO and antibody-based therapies.
  • For more information on Oxford BioTherapeutics, please visit www.oxfordbiotherapeutics.com

Oxford BioTherapeutics to Present Initial Positive Data from Phase I Trial at ASCO 2022

Retrieved on: 
Friday, May 27, 2022

Company has advanced OBT076 into single agent expansion cohorts in both checkpoint- and chemotherapy-nave and resistant patients.

Key Points: 
  • Company has advanced OBT076 into single agent expansion cohorts in both checkpoint- and chemotherapy-nave and resistant patients.
  • Subsequent disease-specific Phase 2a trials are planned in non-small cell lung, ovarian and gastric cancer patients.
  • OBT has a strong oncology focused management team and board with significant experience in developing IO and antibody-based therapies.
  • For more information on Oxford BioTherapeutics, please visit www.oxfordbiotherapeutics.com

Oxford BioTherapeutics Announces Collaboration with Agenus to Support the Clinical Development of OBT's Antibody Drug Conjugate OBT076 in combination with Agenus' CPI Balstilimab

Retrieved on: 
Wednesday, May 25, 2022

OBT plans to evaluate the clinical efficacy of OBT076 in combination with Agenus proprietary CPI, balstilimab.

Key Points: 
  • OBT plans to evaluate the clinical efficacy of OBT076 in combination with Agenus proprietary CPI, balstilimab.
  • Balstilimab is an PD-1 blocking antibody currently in clinical development in several solid tumor indications.
  • "I am very excited about our new partnership with Agenus, which will allow us to progress the clinical development of OBT076 in combination with balstilimab," said Christian Rohlff, PhD, Chief Executive Officer (CEO) of Oxford BioTherapeutics.
  • "We look forward to collaborating with Oxford BioTherapeutics to bring this novel combination to patients," said Steven O'Day, MD, Chief Medical Officer of Agenus.

Oxford BioTherapeutics Announces Collaboration with Agenus to Support the Clinical Development of OBT's Antibody Drug Conjugate OBT076 in combination with Agenus' CPI Balstilimab

Retrieved on: 
Wednesday, May 25, 2022

OBT plans to evaluate the clinical efficacy of OBT076 in combination with Agenus proprietary CPI, balstilimab.

Key Points: 
  • OBT plans to evaluate the clinical efficacy of OBT076 in combination with Agenus proprietary CPI, balstilimab.
  • Balstilimab is an PD-1 blocking antibody currently in clinical development in several solid tumor indications.
  • "I am very excited about our new partnership with Agenus, which will allow us to progress the clinical development of OBT076 in combination with balstilimab," said Christian Rohlff, PhD, Chief Executive Officer (CEO) of Oxford BioTherapeutics.
  • "We look forward to collaborating with Oxford BioTherapeutics to bring this novel combination to patients," said Steven O'Day, MD, Chief Medical Officer of Agenus.

Levena Biopharma, A Sorrento Company, Announces Positive Clinical Data for Its Out-Licensed A166 Product Candidate, A Third-Generation Anti-HER2-ADC, In Treating Heavily Pretreated HER2-Positive Breast Cancer Patients

Retrieved on: 
Tuesday, May 3, 2022

A166 has demonstrated promising antitumor activity with clinically meaningful responses in heavily pretreated subjects with HER2-positive breast cancer.

Key Points: 
  • A166 has demonstrated promising antitumor activity with clinically meaningful responses in heavily pretreated subjects with HER2-positive breast cancer.
  • Sorrento is a clinical and commercial stage biopharmaceutical company developing new therapies to treat cancer, pain (non-opioid treatments), autoimmune disease and COVID-19.
  • Program for SEMDEXA, its novel, non-opioid product for the treatment of lumbosacral radicular pain (sciatica), were announced in March 2022.
  • Forward-looking statements include statements regarding A166 (Anti-HER@-ADC); the therapeutic and clinical potential of A166, including its antitumor activity; the potential safety and efficacy of A166 and the clinical testing of A166.

GeneQuantum and AIMEDBIO Collaborate on a First-in-Class Antibody -Drug-Conjugate

Retrieved on: 
Tuesday, April 19, 2022

GeneQuantum focuses on next generation Antibody Drug Conjugate (ADC) development.

Key Points: 
  • GeneQuantum focuses on next generation Antibody Drug Conjugate (ADC) development.
  • GeneQuantum is excited about the significant potential of partnerships with business partners and will continue to expand its deal pipeline in the antibody drug conjugate (ADC) and protein therapeutic market.
  • Gang Qin, the Founder & Chairman, CEO of GeneQuantum, commented: "As an innovative antibody+ company, we look for complementary partners to maximize value of our platform technology.
  • After evaluating the data, the linker-payload and conjugation technology GeneQuantum provides proved to be very safe and effective.

Oxford BioTherapeutics Grants Third Exclusive License to Boehringer Ingelheim for Development and Commercialization of Antibody Products to a Novel Oncology Target

Retrieved on: 
Wednesday, April 13, 2022

Under the terms of the agreement, Boehringer Ingelheim will be responsible for the future development and commercialization of antibody products to the target.

Key Points: 
  • Under the terms of the agreement, Boehringer Ingelheim will be responsible for the future development and commercialization of antibody products to the target.
  • OBT will receive development and regulatory milestone payments as well as royalties on any future product sales.
  • This represents the third asset to be optioned under the longstanding partnership between OBT and Boehringer Ingelheim, with the first two programs already in clinical development.
  • OBT has a strong oncology focused management team and board with significant experience in developing IO and antibody-based therapies.

Oxford BioTherapeutics Grants Third Exclusive License to Boehringer Ingelheim for Development and Commercialization of Antibody Products to a Novel Oncology Target

Retrieved on: 
Wednesday, April 13, 2022

Under the terms of the agreement, Boehringer Ingelheim will be responsible for the future development and commercialization of antibody products to the target.

Key Points: 
  • Under the terms of the agreement, Boehringer Ingelheim will be responsible for the future development and commercialization of antibody products to the target.
  • OBT will receive development and regulatory milestone payments as well as royalties on any future product sales.
  • This represents the third asset to be optioned under the longstanding partnership between OBT and Boehringer Ingelheim, with the first two programs already in clinical development.
  • OBT has a strong oncology focused management team and board with significant experience in developing IO and antibody-based therapies.

AACR 2022: Oxford BioTherapeutics to Present Potential Novel Immuno-Oncology Mechanism in Combination with Checkpoint Inhibitors for Experimental ADC Medicine OBT076

Retrieved on: 
Thursday, April 7, 2022

"The results support our excitement around OBT076 as a therapeutic capable of harnessing the immune system to treat patients with advanced, difficult to treat cancers both as monotherapy and in combination with a CPI.

Key Points: 
  • "The results support our excitement around OBT076 as a therapeutic capable of harnessing the immune system to treat patients with advanced, difficult to treat cancers both as monotherapy and in combination with a CPI.
  • Following 2 further cycles of OBT076 and 1 cycle of CPI, complete response was achieved for the primary tumor.
  • These data give us hope that OBT076 could achieve favorable clinical outcomes in such patients when used in combination with immune CPIs.
  • The abstract and presentation details are as follows:
    Title: Potential Novel Immuno-oncology Mechanism revealed during Translational Phase I Immuno- blood Profiling of Experimental ADC medicine OBT076 in A Gastric Cancer Patient.

AACR 2022: Oxford BioTherapeutics to Present Potential Novel Immuno-Oncology Mechanism in Combination with Checkpoint Inhibitors for Experimental ADC Medicine OBT076

Retrieved on: 
Thursday, April 7, 2022

"The results support our excitement around OBT076 as a therapeutic capable of harnessing the immune system to treat patients with advanced, difficult to treat cancers both as monotherapy and in combination with a CPI.

Key Points: 
  • "The results support our excitement around OBT076 as a therapeutic capable of harnessing the immune system to treat patients with advanced, difficult to treat cancers both as monotherapy and in combination with a CPI.
  • Following 2 further cycles of OBT076 and 1 cycle of CPI, complete response was achieved for the primary tumor.
  • These data give us hope that OBT076 could achieve favorable clinical outcomes in such patients when used in combination with immune CPIs.
  • The abstract and presentation details are as follows:
    Title: Potential Novel Immuno-oncology Mechanism revealed during Translational Phase I Immuno- blood Profiling of Experimental ADC medicine OBT076 in A Gastric Cancer Patient.